At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 200 enrolled
Drug / intervention
XIENCE V® Everolimus Eluting Coronary Stent System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.
In Brief
A Phase 4 clinical trial evaluating XIENCE V® Everolimus Eluting Coronary Stent System and TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System for Coronary Disease and 3 related conditions. Completed, enrolled 200 participants across 24 sites.
Detailed Summary
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary Artery Disease (MVD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedSep 2007
Primary CompletionMar 2010
Study CompletionJun 2011
TodayJul 2026
First PostedSep 18, 2007
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2010
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.8 years ago
Interventions
XIENCE V® Everolimus Eluting Coronary Stent Systemdevice
Coronary artery placement of a drug-eluting stent
TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent Systemdevice
Coronary artery placement of a drug-eluting stent